VRCA.NASDAQVerrica Pharmaceuticals INC

10-Q: Verrica Pharmaceuticals Faces Going Concern Uncertainty Despite YCANTH Revenue

Sentiment:

Quarterly Report

📋All filings for Verrica Pharmaceuticals INC
🔒Login to Follow

Verrica Pharmaceuticals reports Q1 2025 results, highlighting revenue growth but also raising concerns about its ability to continue as a going concern due to liquidity challenges and debt obligations.

Capital raiseThe company plans to secure additional capital in the future through equity or debt financings, partnerships, or other sources to carry out its planned commercial and development activities.The company is subject to the general instructions of Form S-3 known as the 'baby shelf rules.'Under these rules, the amount of funds the company can raise through primary public offerings of securities in any 12-month period using its registration statement on Form S-3 is limited to one-third of the aggregate market value of the shares of the company's common stock held by its non-affiliates.
Worse than expectedThe company's statement about substantial doubt regarding its ability to continue as a going concern indicates worse than expected financial stability.The decrease in collaboration revenue and the relatively low cash balance also contribute to the assessment of worse than expected results.

Summary

  • Verrica Pharmaceuticals reported a net loss of $9.7 million for the three months ended March 31, 2025, compared to a net loss of $20.3 million for the same period in 2024.
  • Product revenue, net, increased to $3.4 million from $3.2 million year-over-year.
  • Collaboration revenue decreased significantly to $17,000 from $0.6 million year-over-year.
  • The company's cash and cash equivalents stood at $29.6 million as of March 31, 2025.
  • Verrica has substantial debt obligations, including a requirement to maintain a minimum liquidity of $10.0 million.
  • The company acknowledges substantial doubt about its ability to continue as a going concern within one year after the financial statements are issued.
  • Verrica plans to secure additional funding through equity offerings, debt financing, collaborations, and strategic alliances.
  • Operating expenses decreased to $11.6 million from $22.4 million year-over-year, primarily due to reduced selling, general, and administrative expenses.
  • Research and development expenses also decreased to $2.3 million from $4.9 million year-over-year.
  • The company is developing YCANTH (VP-102) for common warts and VP-315 for basal cell carcinoma.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While there are positive aspects such as increased product revenue and decreased operating expenses, the going concern warning and need for additional funding weigh heavily on the overall outlook.

Positives

  • Product revenue increased to $3.4 million, indicating growing sales of YCANTH.
  • Operating expenses decreased significantly, reflecting cost-cutting measures.
  • Research and development expenses decreased, potentially indicating more efficient use of resources.
  • The company is actively pursuing additional indications for YCANTH and developing VP-315.
  • The company is in compliance with all covenants under the Credit Agreement, as amended, as of March 31, 2025.

Negatives

  • The company has an accumulated deficit of $316.8 million as of March 31, 2025.
  • Collaboration revenue decreased significantly, impacting overall revenue.
  • The company acknowledges substantial doubt about its ability to continue as a going concern.
  • The company's cash and cash equivalents are relatively low at $29.6 million.
  • The company is obligated to repay the principal amount of the loan on the last day of each month in equal monthly installments through the Maturity Date, together with the applicable repayment premium and the exit fee.

Risks

  • The company's ability to continue as a going concern is uncertain due to liquidity challenges and debt obligations.
  • Failure to secure additional funding could force the company to delay or eliminate commercialization and development programs.
  • The company's debt agreement includes a financial covenant to maintain a minimum liquidity of $10.0 million.
  • The company's quarterly and annual financial statements must not be subject to any qualification or statement which is of a going concern or similar nature.
  • The company's ability to raise capital through its shelf registration statement is limited by the 'baby shelf rules'.
  • Clinical trials may be delayed or modified, impacting development timelines and costs.
  • Regulatory approvals for product candidates are uncertain.
  • The company may not achieve commercial success with its products.

Future Outlook

The company plans to secure additional capital through equity or debt financings, partnerships, or other sources to carry out its planned commercial and development activities. The company expects to continue to incur significant expenses and operating losses for the foreseeable future.

Industry Context

Verrica Pharmaceuticals operates in the dermatology therapeutics market, focusing on clinician-administered therapies. The company's lead product, YCANTH, competes with other treatments for molluscum contagiosum and faces potential competition from emerging therapies. The company's success depends on its ability to effectively commercialize YCANTH and develop its pipeline products.

Comparison to Industry Standards

  • It is difficult to compare Verrica's results directly to industry standards without specific benchmarks for companies focusing on similar niche dermatology markets.
  • However, companies like Cassiopea S.p.A. and Journey Medical Corporation also focus on dermatology products and could be considered peers, though their specific product portfolios and financial situations may differ significantly.
  • Comparing Verrica's revenue growth and operating expenses to these companies, while considering their respective market capitalizations and development stages, could provide a broader industry context.
  • Additionally, analyzing the market penetration and pricing strategies of YCANTH compared to other topical treatments for similar skin conditions could offer insights into its competitive positioning.

Legal Proceedings

  • The company is involved in a putative class action complaint, Gorlamari v. Verrica Pharmaceuticals Inc., et al., in the U.S. District Court for the Eastern District of Pennsylvania.
  • The company is involved in a putative stockholder derivative lawsuit in the U.S. District Court for the Eastern District of Pennsylvania.
  • The company is involved in ordinary, routine legal proceedings that are not considered by management to be material.

Related Party Transactions

  • Our Chief Executive Officer, Jayson Rieger, and our Chief Operating Officer, David Zawitz, are former employees of, and current consultants to, PBM Capital Group, LLC, an entity controlled by Paul B. Manning, a significant investor of the Company.

Stakeholder Impact

  • Shareholders face potential dilution from future equity offerings.
  • Employees face uncertainty due to the company's financial situation and potential cost-cutting measures.
  • Customers may be affected if the company is unable to continue supplying YCANTH.
  • Creditors face increased risk due to the company's going concern uncertainty.

Next Steps

  • The company plans to continue commercializing YCANTH for molluscum contagiosum.
  • The company plans to advance YCANTH (VP-102) for common warts through a separate regulatory approval process and conduct a global phase three program with its partner, Torii.
  • The company plans to continue developing VP-315 for the treatment of BCC and potentially additional dermatological oncology indications.
  • The company plans to seek additional funding through equity offerings, debt financing, collaborations, and strategic alliances.

Key Dates

DateDescription
July 3, 2013Verrica Pharmaceuticals Inc. was formed.
May 19, 2021Beginning of the Putative Class Period in the Gorlamari v. Verrica Pharmaceuticals Inc. lawsuit.
March 17, 2021Verrica entered into a collaboration and license agreement with Torii Pharmaceutical Co., Ltd.
May 24, 2022End of the Putative Class Period in the Gorlamari v. Verrica Pharmaceuticals Inc. lawsuit.
June 6, 2022Plaintiff Kranthi Gorlamari filed a putative class action complaint against Verrica Pharmaceuticals Inc.
May 1, 2022Commencement date of the operating lease for office space in Scotch Plains, New Jersey.
July 21, 2023The FDA approved YCANTH (VP-102) topical solution for the treatment of molluscum contagiosum.
July 26, 2023Verrica entered into a Credit Agreement and borrowed $50.0 million.
August 2023Verrica commercially launched YCANTH (VP-102) in the United States.
August 24, 2023First commercial sale of YCANTH (VP-102) occurred.
December 20, 2023Verrica entered into an amendment to the Credit Agreement to extend a deadline for a specified regulatory milestone.
January 31, 2024Verrica entered into a second amendment to the Credit Agreement.
February 2024Verrica filed a lawsuit against Dormer Laboratories Inc.
March 2024The Company granted 272,500 RSUs to executive officers.
April 22, 2024Defendants motion to dismiss the second amended complaint was fully briefed.
May 6, 2024Verrica entered into the Third Amendment to the Credit Agreement.
May 14, 2024Verrica entered into the First Amendment to the Torii Agreement.
June 2024Verrica and Dormer Labs announced the settlement of litigation.
June 26, 2024Verrica entered into the Fourth Amendment to the Credit Agreement.
August 2, 2024Verrica entered into the Fifth Amendment and waiver to the Credit Agreement.
September 3, 2024The Court granted in part and denied in part Defendants motion to dismiss the second amended complaint.
September 2024The Company terminated the agreement effective November 30, 2024.
October 21, 2024Plaintiff Ivan S. Cohen filed a putative stockholder derivative lawsuit.
November 2024Verrica closed an underwritten offering of common stock and warrants, resulting in net proceeds of $39.6 million.
November 22, 2024The Company sold 45,518,243 shares of its common stock and pre-funded warrants to purchase 2,235,955 shares of common stock.
December 16, 2024The Court granted the parties' joint stipulation to stay the derivative lawsuit.
December 31, 2024Based on the Company's net revenue attributable to YCANTH on a trailing 12-month basis not meeting a specified amount set forth in the Credit Agreement, the Company became obligated to start making principal payments starting in January 2025.
January 1, 2025The Company became obligated to start making principal payments starting on January 1, 2025.
January 12, 2023The Plaintiff filed an amended complaint alleging that Defendants violated federal securities laws.
January 12, 2024The Court granted in part and denied in part Defendants motion to dismiss the amended complaint.
January 26, 2024Plaintiff filed a second amended complaint in an attempt to cure certain of the deficiencies identified in the January 12, 2024 ruling.
February 18, 2025Verrica entered into a waiver to the Credit Agreement.
March 31, 2025End of the quarterly period covered by the report.
May 7, 2025As of this date, the registrant had 92,490,993 shares of common stock outstanding.
May 13, 2025Date of the report.
April 24, 2025Release Agreement, dated April 24, 2025, by and between the Company and Christopher G. Hayes

Keywords

Verrica Pharmaceuticals, YCANTH, VP-102, VP-315, Molluscum Contagiosum, Basal Cell Carcinoma, Going Concern, Liquidity, Financial Results, Dermatology, Pharmaceuticals

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.